IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
INDICATION
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Reference: 1. EUCRISA® (crisaborole) Full Prescribing Information. March 2020.
Please see Full Prescribing Information.
PP-CRI-USA-2371-01 © 2020 Pfizer Inc.
All rights reserved. April 2020
All rights reserved. April 2020
Please see Full Prescribing Information.